(GEHC) GE HealthCare Technologies - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US36266G1076
Imaging, Ultrasound, Monitoring, Contrast, Radiopharmaceuticals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.22% |
| Yield on Cost 5y | 0.23% |
| Yield CAGR 5y | 24.72% |
| Payout Consistency | 100.0% |
| Payout Ratio | 3.0% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 30.9% |
| Value at Risk 5%th | 46.4% |
| Relative Tail Risk | -8.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -23.86 |
| CAGR/Max DD | 0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.405 |
| Beta | 1.309 |
| Beta Downside | 1.618 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.35% |
| Mean DD | 13.41% |
| Median DD | 12.89% |
Description: GEHC GE HealthCare Technologies December 17, 2025
GE HealthCare Technologies Inc. (NASDAQ: GEHC) develops, manufactures, and markets medical imaging, advanced visualization, patient-care, and pharmaceutical-diagnostic products and digital solutions across the U.S., Canada, and global markets. The business is organized into four segments: Imaging (CT, MR, X-ray, molecular imaging, womens health), Advanced Visualization Solutions (ultrasound, interventional and surgical guidance), Patient Care Solutions (monitoring, cardiology, consumables, anesthesia, maternal-infant care), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals). The company, renamed from GE Healthcare Holding LLC in December 2022, is headquartered in Chicago.
Key recent data points: FY 2023 revenue was ≈ $19.2 billion, with the Imaging segment contributing roughly 55 % of total sales; operating margin stood at 12 % and free cash flow at $2.5 billion. Growth is being driven by AI-enabled imaging workflows, expanding outpatient imaging volumes, and an aging population that fuels demand for diagnostic services. However, margin pressure from supply-chain constraints and evolving reimbursement policies remains a material risk.
For a deeper quantitative dive, consider reviewing GE HC’s detailed financials and valuation metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 2.22b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.13 > 1.0 |
| NWC/Revenue: 8.99% < 20% (prev 8.22%; Δ 0.77% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.85b > Net Income 2.22b |
| Net Debt (6.74b) to EBITDA (3.80b): 1.77 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (457.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 40.80% > 18% (prev 0.41%; Δ 4039 % > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 57.77%; Δ 0.09% > 0%) |
| Interest Coverage Ratio: 7.24 > 6 (EBITDA TTM 3.80b / Interest Expense TTM 446.0m) |
Altman Z'' (< 1.1 .. > 2.6) 1.52
| A: 0.05 (Total Current Assets 11.89b - Total Current Liabilities 10.07b) / Total Assets 36.13b |
| B: 0.13 (Retained Earnings 4.71b / Total Assets 36.13b) |
| C: 0.09 (EBIT TTM 3.23b / Avg Total Assets 34.99b) |
| D: 0.14 (Book Value of Equity 3.56b / Total Liabilities 25.91b) |
| Altman-Z'' Score: 1.52 = BB |
ValueRay F-Score (Strict, 0-100) 66.89
| 1. Piotroski: 5.0pt |
| 2. FCF Yield: 3.18% |
| 3. FCF Margin: 6.92% |
| 4. Debt/Equity: 1.08 |
| 5. Debt/Ebitda: 1.77 |
| 6. ROIC - WACC: 3.82% |
| 7. RoE: 23.74% |
| 8. Revenue Trend: 71.74% |
| 9. EPS Trend: -19.01% |
What is the price of GEHC shares?
As of January 23, 2026, the stock is trading at USD 81.10 with a total of 4,418,945 shares traded.
Over the past week, the price has changed by -4.92%, over one month by -3.35%, over three months by +6.66% and over the past year by -6.97%.
Over the past week, the price has changed by -4.92%, over one month by -3.35%, over three months by +6.66% and over the past year by -6.97%.
Is GEHC a buy, sell or hold?
GE HealthCare Technologies has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy GEHC.
- Strong Buy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GEHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 92 | 13.4% |
| Analysts Target Price | 92 | 13.4% |
| ValueRay Target Price | 81.8 | 0.8% |
GEHC Fundamental Data Overview January 19, 2026
P/E Trailing = 16.9255
P/E Forward = 17.2414
P/S = 1.8435
P/B = 3.7265
P/EG = 2.4481
Revenue TTM = 20.25b USD
EBIT TTM = 3.23b USD
EBITDA TTM = 3.80b USD
Long Term Debt = 8.28b USD (from longTermDebt, last quarter)
Short Term Debt = 2.14b USD (from shortTermDebt, last quarter)
Debt = 10.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.74b USD (from netDebt column, last quarter)
Enterprise Value = 44.06b USD (37.32b + Debt 10.74b - CCE 4.00b)
Interest Coverage Ratio = 7.24 (Ebit TTM 3.23b / Interest Expense TTM 446.0m)
EV/FCF = 31.47x (Enterprise Value 44.06b / FCF TTM 1.40b)
FCF Yield = 3.18% (FCF TTM 1.40b / Enterprise Value 44.06b)
FCF Margin = 6.92% (FCF TTM 1.40b / Revenue TTM 20.25b)
Net Margin = 10.95% (Net Income TTM 2.22b / Revenue TTM 20.25b)
Gross Margin = 40.80% ((Revenue TTM 20.25b - Cost of Revenue TTM 11.98b) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 39.61%)
Tobins Q-Ratio = 1.22 (Enterprise Value 44.06b / Total Assets 36.13b)
Interest Expense / Debt = 1.03% (Interest Expense 111.0m / Debt 10.74b)
Taxrate = 27.84% (179.0m / 643.0m)
NOPAT = 2.33b (EBIT 3.23b * (1 - 27.84%))
Current Ratio = 1.18 (Total Current Assets 11.89b / Total Current Liabilities 10.07b)
Debt / Equity = 1.08 (Debt 10.74b / totalStockholderEquity, last quarter 9.99b)
Debt / EBITDA = 1.77 (Net Debt 6.74b / EBITDA 3.80b)
Debt / FCF = 4.81 (Net Debt 6.74b / FCF TTM 1.40b)
Total Stockholder Equity = 9.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.33% (Net Income 2.22b / Total Assets 36.13b)
RoE = 23.74% (Net Income TTM 2.22b / Total Stockholder Equity 9.34b)
RoCE = 18.33% (EBIT 3.23b / Capital Employed (Equity 9.34b + L.T.Debt 8.28b))
RoIC = 12.32% (NOPAT 2.33b / Invested Capital 18.90b)
WACC = 8.51% (E(37.32b)/V(48.07b) * Re(10.74%) + D(10.74b)/V(48.07b) * Rd(1.03%) * (1-Tc(0.28)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF Debug] Terminal Value 75.78% ; FCFF base≈1.52b ; Y1≈1.47b ; Y5≈1.47b
Fair Price DCF = 37.15 (EV 23.66b - Net Debt 6.74b = Equity 16.92b / Shares 455.5m; r=8.51% [WACC]; 5y FCF grow -4.08% → 2.90% )
EPS Correlation: -19.01 | EPS CAGR: -16.19% | SUE: 0.31 | # QB: 0
Revenue Correlation: 71.74 | Revenue CAGR: 3.09% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.99 | Chg30d=-0.004 | Revisions Net=-2 | Analysts=13
EPS next Year (2026-12-31): EPS=4.93 | Chg30d=-0.006 | Revisions Net=-2 | Growth EPS=+8.2% | Growth Revenue=+4.3%
P/E Forward = 17.2414
P/S = 1.8435
P/B = 3.7265
P/EG = 2.4481
Revenue TTM = 20.25b USD
EBIT TTM = 3.23b USD
EBITDA TTM = 3.80b USD
Long Term Debt = 8.28b USD (from longTermDebt, last quarter)
Short Term Debt = 2.14b USD (from shortTermDebt, last quarter)
Debt = 10.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.74b USD (from netDebt column, last quarter)
Enterprise Value = 44.06b USD (37.32b + Debt 10.74b - CCE 4.00b)
Interest Coverage Ratio = 7.24 (Ebit TTM 3.23b / Interest Expense TTM 446.0m)
EV/FCF = 31.47x (Enterprise Value 44.06b / FCF TTM 1.40b)
FCF Yield = 3.18% (FCF TTM 1.40b / Enterprise Value 44.06b)
FCF Margin = 6.92% (FCF TTM 1.40b / Revenue TTM 20.25b)
Net Margin = 10.95% (Net Income TTM 2.22b / Revenue TTM 20.25b)
Gross Margin = 40.80% ((Revenue TTM 20.25b - Cost of Revenue TTM 11.98b) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 39.61%)
Tobins Q-Ratio = 1.22 (Enterprise Value 44.06b / Total Assets 36.13b)
Interest Expense / Debt = 1.03% (Interest Expense 111.0m / Debt 10.74b)
Taxrate = 27.84% (179.0m / 643.0m)
NOPAT = 2.33b (EBIT 3.23b * (1 - 27.84%))
Current Ratio = 1.18 (Total Current Assets 11.89b / Total Current Liabilities 10.07b)
Debt / Equity = 1.08 (Debt 10.74b / totalStockholderEquity, last quarter 9.99b)
Debt / EBITDA = 1.77 (Net Debt 6.74b / EBITDA 3.80b)
Debt / FCF = 4.81 (Net Debt 6.74b / FCF TTM 1.40b)
Total Stockholder Equity = 9.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.33% (Net Income 2.22b / Total Assets 36.13b)
RoE = 23.74% (Net Income TTM 2.22b / Total Stockholder Equity 9.34b)
RoCE = 18.33% (EBIT 3.23b / Capital Employed (Equity 9.34b + L.T.Debt 8.28b))
RoIC = 12.32% (NOPAT 2.33b / Invested Capital 18.90b)
WACC = 8.51% (E(37.32b)/V(48.07b) * Re(10.74%) + D(10.74b)/V(48.07b) * Rd(1.03%) * (1-Tc(0.28)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF Debug] Terminal Value 75.78% ; FCFF base≈1.52b ; Y1≈1.47b ; Y5≈1.47b
Fair Price DCF = 37.15 (EV 23.66b - Net Debt 6.74b = Equity 16.92b / Shares 455.5m; r=8.51% [WACC]; 5y FCF grow -4.08% → 2.90% )
EPS Correlation: -19.01 | EPS CAGR: -16.19% | SUE: 0.31 | # QB: 0
Revenue Correlation: 71.74 | Revenue CAGR: 3.09% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.99 | Chg30d=-0.004 | Revisions Net=-2 | Analysts=13
EPS next Year (2026-12-31): EPS=4.93 | Chg30d=-0.006 | Revisions Net=-2 | Growth EPS=+8.2% | Growth Revenue=+4.3%
Additional Sources for GEHC Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle